Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Martin-Broto, J; Pousa, AL; de las Penas, R; del Muro, XG; Gutierrez, A; Martinez-Trufero, J; Cruz, J; Alvarez, R; Cubedo, R; Redondo, A; Maurel, J; Carrasco, JA; Lopez-Martin, JA; Sala, A; Meana, JA; Ramos, R; Martinez-Serra, J; Lopez-Guerrero, JA; Sevilla, I; Balana, C; Vaz, A; De Juan, A; Alemany, R; Poveda, A.

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

JOURNAL OF CLINICAL ONCOLOGY. 2016; 34(19): 2294 Nº de citas: 63 [doi:10.1200/JCO.2015.65.3329]

Bermejo-Martin, JF; Avila-Alonso, A; Gonzalez-Rivera, M; Tamayo, E; Eiros, JM; Almansa, R.

Postbooster Antibodies from Humans as Source of Diphtheria Antitoxin

EMERGING INFECTIOUS DISEASES. 2016; 22(7): 1265-1267 Nº de citas: 5 [doi:10.3201/eid2207.151670]

Martin, M; Fumoleau, P; Dewar, JA; Albanell, J; Limentani, SA; Campone, M; Chang, JC; Patre, M; Strasak, A; de Haas, SL; Xu, J; Garcia-Saenz, JA.

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study

ANNALS OF ONCOLOGY. 2016; 27(7): 1249-1256 Nº de citas: 50 [doi:10.1093/annonc/mdw157]

Martin, AJM; Alfonso, PG; Ruperez, AB; Jimenez, MM.

Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2

Oncology Letters. 2016; 12(1): 727-730 Nº de citas: 8 [doi:10.3892/ol.2016.4667]

de Maturana, EL; Picornell, A; Masson-Lecomte, A; Kogevinas, M; Marquez, M; Carrato, A; Tardon, A; Lloreta, J; Garcia-Closas, M; Silverman, D; Rothman, N; Chanock, S; Real, FX; Goddard, ME; Malats, N; SBC EPICURO Study Investigators.

Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models

BMC CANCER. 2016; 16: Nº de citas: 4 [doi:10.1186/s12885-016-2361-7]

Cortejoso, L; Garcia-Gonzalez, X; Garcia, MI; Garcia-Alfonso, P; Sanjurjo, M; Lopez-Fernandez, LA.

Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines

PHARMACOGENOMICS. 2016; 17(9): 979-984 Nº de citas: 40 [doi:10.2217/pgs-2016-0006]

Espinosa, E; Soriano, V; Malvehy, J; Berrocal, A; de Prado, PM; Quindos, M; Soria, A; Marquez-Rodas, I; Palacio, I; Cerezuela, P; Lopez-Vivanco, G; Alonso, L; Samaniego, E; Ballesteros, A; Puertolas, T; Diaz-Beveridge, R; de la Cruz-Merino, L; Castro, RL; Lopez, RL; Stevinson, K; del Barrio, P; Tornamira, MV; Guillem, V; Martin-Algarra, S.

Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study

MELANOMA RESEARCH. 2016; 26(3): 278-283 Nº de citas: 9 [doi:10.1097/CMR.0000000000000254]

Mackey, JR; Pienkowski, T; Crown, J; Sadeghi, S; Martin, M; Chan, A; Saleh, M; Sehdev, S; Provencher, L; Semiglazov, V; Press, MF; Sauter, G; Lindsay, M; Houe, V; Buyse, M; Drevot, P; Hitier, S; Bensfia, S; Eiermann, W.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

ANNALS OF ONCOLOGY. 2016; 27(6): 1041-1047 Nº de citas: 55 [doi:10.1093/annonc/mdw098]

Perez-Valderrama, B; Arija, JAA; Sanchez, AR; Marin, AP; Garcia, PB; Gaunas, DEC; Romero, GR; Alonso, CM; Guzman, JCV; Alvarez, JLP; Gonzalez, IC; Vidal, MJM; Fita, MJJ; Leon-Mateos, L; Quintela, ML; Dominguez, RG; Garcia, JMJ; de Mendizabal, EV; Sorrosal, JJL; Carbonero, IG; del Alba, AG; Rodriguez, CS; Gallego, PJ; Garcia, JAM; Marrero, RDG; Borau, PG; Lobera, CS; Palau, CM; Brea, ML; Parra, EMF; Torras, OR; Badiola, LB; Estevez, SV; Larriba, JLG.

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study

ANNALS OF ONCOLOGY. 2016; 27(4): 706-711 Nº de citas: 27 [doi:10.1093/annonc/mdv601]

Maroto, P; Solsona, E; Gallardo, E; Mellado, B; Morote, J; Arranz, JA; Gomez-Veiga, F; Unda, M; Climent, MA; Alcaraz, A.

Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2016; 100: 127-136 Nº de citas: 13 [doi:10.1016/j.critrevonc.2015.07.011]

Puente, J; del Muro, XG; Pinto, A; Lainez, N; Esteban, E; Arranz, JA; Gallardo, E; Mendez, MJ; Maroto, P; Grande, E; Suarez, C.

Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

TARGETED ONCOLOGY. 2016; 11(2): 129-141 Nº de citas: 4 [doi:10.1007/s11523-015-0408-3]

Gonzalez-Rivera, M; Lobo, M; Lopez-Tarruella, S; Jerez, Y; del Monte-Millan, M; Massarrah, T; Ramos-Medina, R; Ocana, I; Picornell, A; Garzon, SS; Perez-Carbornero, L; Garcia-Saenz, JA; Gomez, H; Moreno, F; Marquez-Rodas, I; Fuentes, H; Martin, M.

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

BREAST CANCER RESEARCH AND TREATMENT. 2016; 156(3): 507-515 Nº de citas: 23 [doi:10.1007/s10549-016-3792-1]

Duran, I; Hagen, C; Arranz, JA; Apellaniz-Ruiz, M; Perez-Valderrama, B; Sala, N; Lainez, N; Garcia-Del Muro, X; Nogueron, E; Climent, MA; Maroto, P; Font, A; Garcia-Donas, J; Gallardo, E; Lopez-Criado, P; Del Alba, AG; Saez, MI; Vazquez, S; Luque, R; Rodriguez-Antona, C.

SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma

PHARMACOGENOMICS. 2016; 17(5): 463-471 Nº de citas: 5 [doi:10.2217/pgs.15.186]

Chan, A; Delaloge, S; Holmes, FA; Moy, B; Iwata, H; Harvey, VJ; Robert, NJ; Silovski, T; Gokmen, E; Von Minckwitz, G; Ejlertsen, B; Chia, SKL; Mansi, J; Barrios, CH; Gnant, M; Buyse, M; Gore, I; Smith, J; Harker, G; Masuda, N; Petrakova, K; Zotano, AG; Iannotti, ZN; Rodriguez, G; Tassone, P; Wong, A; Bryce, R; Ye, YN; Yao, B; Martin, M.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

LANCET ONCOLOGY. 2016; 17(3): 367-377 Nº de citas: 479 [doi:10.1016/S1470-2045(15)00551-3]

Pereira, A; Perez-Medina, T; Magrina, JF; Magtibay, PM; Rodriguez-Tapia, A; Cuesta-Guardiola, T; Peregrin, I; Mendizabal, E; Lizarraga, S; Ortiz-Quintana, L.

"The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period"

SURGICAL ONCOLOGY-OXFORD. 2016; 25(1): 49-59 Nº de citas: 6 [doi:10.1016/j.suronc.2015.12.005]

Strasser-Weippl, K; Horick, N; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Boyle, F; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Rappold, E; Finkelstein, DM; Goss, PE.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

EUROPEAN JOURNAL OF CANCER. 2016; 56: 85-92 Nº de citas: 4 [doi:10.1016/j.ejca.2015.12.024]

Hadji, P; Coleman, RE; Wilson, C; Powles, TJ; Clezardin, P; Aapro, M; Costa, L; Body, JJ; Markopoulos, C; Santini, D; Diel, I; Di Leo, A; Cameron, D; Dodwell, D; Smith, I; Gnant, M; Gray, R; Harbeck, N; Thurlimann, B; Untch, M; Cortes, J; Martin, M; Albert, US; Conte, PF; Ejlertsen, B; Bergh, J; Kaufmann, M; Holen, I.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

ANNALS OF ONCOLOGY. 2016; 27(3): 379-390 Nº de citas: 134 [doi:10.1093/annonc/mdv617]

Mesia, R; Vazquez, S; Grau, JJ; Garcia-Saenz, JA; Lozano, A; Garcia, C; Carles, J; Irigoyen, A; Manos, M; Garcia-Paredes, B; del Barco, E; Taberna, M; Escobar, Y; Cruz, JJ.

A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2016; 94(2): 289-296 Nº de citas: 22 [doi:10.1016/j.ijrobp.2015.10.019]